Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119252) titled 'Prospective, multi-center, single-arm phase II clinical study of the efficacy and safety of vorolanib monotherapy as adjuvant treatment in intermediate-high risk resectable renal cell carcinoma' on Feb. 25.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Chongqing University Cancer Hospital

Condition: Renal cell carcinoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-03-02

Target Sample Size: Experimental Group:200;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=283151

Disclaimer: Curated by ...